跳转至内容
Merck
CN

EHU049321

MISSION® esiRNA

targeting human CITED2

登录 查看组织和合同定价。

选择尺寸

关于此项目

NACRES:
NA.51
UNSPSC Code:
41105324

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GCCGCCCAATGTCATAGACACTGATTTCATCGACGAGGAAGTTCTTATGTCCTTGGTGATAGAAATGGGTTTGGACCGCATCAAGGAGCTGCCCGAACTCTGGCTGGGGCAAAACGAGTTTGATTTTATGACGGACTTCGTGTGCAAACAGCAGCCCAGCAGAGTGAGCTGTTGACTCGATCGAAACCCCGGCGAAAGAAATCAAACCCCCAACTTCTTCGGCGTGAATTAAAAGAAACATTCCCTTAGACACAGTATCTCACTTTTCAGATCTTGAAAGGTTTGAGAACTTGGAAACAAAGTAAACTATAAACTTGTACAAATTGGTTTTAAAAAAAATTGCTGCCACTTTTTTTTCCTGTTTTTGTTTCGTTTTTGTAGCCTTGACATTCACCCACCTCC

Ensembl | human accession no.

ENSG00000164442

NCBI accession no.

NM_006079

shipped in

ambient

storage temp.

−20°C

Quality Level

100

相关类别

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
FNS
WNS
JRR

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Katharina Mattes et al.
Cell death & disease, 8(10), e3132-e3132 (2017-10-27)
CITED2 (CBP/p300-interacting-transactivator-with-an-ED-rich-tail 2) is a regulator of the acetyltransferase CBP/p300 and elevated CITED2 levels are shown in a number of acute myeloid leukemia (AML). To study the in vivo role of CITED2 in AML maintenance, AML cells were transduced with
Seung-Hyun Shin et al.
Nature communications, 9(1), 4113-4113 (2018-10-07)
Despite many efforts to develop hormone therapy and chemotherapy, no effective strategy to suppress prostate cancer metastasis has been established because the metastasis is not well understood. We here investigate a role of CBP/p300-interacting transactivator with E/D-rich carboxy-terminal domain-2 (CITED2)

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持